<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mefloquine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mefloquine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mefloquine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10834" href="/d/html/10834.html" rel="external">see "Mefloquine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13029" href="/d/html/13029.html" rel="external">see "Mefloquine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F21288105"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Neuropsychiatric effects:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Mefloquine may cause neuropsychiatric adverse reactions that can persist after mefloquine has been discontinued.</p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine should not be prescribed for prophylaxis in patients with major psychiatric disorders. During prophylactic use, if psychiatric or neurologic symptoms occur, the drug should be discontinued, and an alternative medication should be substituted.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F192267"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antimalarial Agent</li></ul></div>
<div class="block doa drugH1Div" id="F192231"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;">
<b>Note: </b>Dose expressed as mg of mefloquine hydrochloride. Due to geographical resistance and cross-resistance, consult current CDC or World Health Organization guidelines as appropriate.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b917b469-9f40-453d-845b-8105134d59ae">Malaria, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, prophylaxis:</b>
<b>Oral:</b> 250 mg once weekly starting ≥2 weeks before arrival in endemic area, continuing weekly during travel and for 4 weeks after leaving endemic area (CDC Yellow Book 2020).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="291da3f6-4546-4769-b192-f22ead1b5b60">Malaria, uncomplicated, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, uncomplicated, treatment (alternative agent): </b></p>
<p style="text-indent:-4em;margin-left:6em;">
<b>Note:</b> Use only if no other treatment options are available (CDC 2020). When available, artemisinin-based combination therapy is the preferred treatment for malaria; outside of the United States, mefloquine is available in a fixed-dosed combination product with artesunate (WHO 2022).</p>
<p style="text-indent:-4em;margin-left:6em;">
<b>Oral: </b>750 mg as a single dose initially, followed 6 to 12 hours later with 500 mg as a single dose; for <i>P. vivax</i> or <i>Plasmodium ovale</i> malaria, use in combination with primaquine (CDC 2020).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991391"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary; only a small amount of mefloquine is renally eliminated.</p></div>
<div class="block doha drugH1Div" id="F50988580"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, half-life may be prolonged and plasma levels may be higher in patients with hepatic impairment.</p></div>
<div class="block doe drugH1Div" id="F192232"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F192251"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13029" href="/d/html/13029.html" rel="external">see "Mefloquine: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dose is expressed as mg of mefloquine hydrochloride.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b917b469-9f40-453d-845b-8105134d59ae">Malaria, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, prophylaxis:</b>
<b>Note:</b> Begin ≥2 weeks before arrival in endemic area and continue weekly during travel (on the same day each week) and for 4 weeks after leaving endemic area. Starting 3 to 4 weeks in advance of travel may allow potential adverse effects to occur prior to travel (CDC 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing</i>: Infants, Children, and Adolescents: Oral: 5 mg/kg/dose once weekly; maximum dose: 250 mg/dose (CDC 2023; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing</i>: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;9 to 19 kg: Oral: 62.5 mg (<sup>1</sup>/<sub>4</sub> of 250 mg tablet) once weekly (CDC 2023).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;19 to 30 kg: Oral: 125 mg (<sup>1</sup>/<sub>2</sub> of 250 mg tablet) once weekly (CDC 2023).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;30 to 45 kg: Oral: 187.5 mg (<sup>3</sup>/<sub>4</sub> of 250 mg tablet) once weekly (CDC 2023).</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;45 kg: Oral: 250 mg once weekly (CDC 2023).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="291da3f6-4546-4769-b192-f22ead1b5b60">Malaria, uncomplicated, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, uncomplicated, treatment: Note:</b> Recommended only if no other treatment options are available; not recommended for infections caused by <i>P. falciparum</i> or unknown species acquired in Southeast Asia due to resistance (CDC 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Limited data available in ages &lt;6 months: Oral: 15 mg/kg once (maximum dose: 750 mg/dose) followed 6 to 12 hours later with 10 mg/kg once (maximum dose: 500 mg/dose). For treatment of <i>P. vivax</i> or <i>Plasmodium ovale</i>, use in combination with primaquine to prevent relapse (CDC 2023).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130260"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants ≥6 months, Children, and Adolescents: No dosage adjustment necessary; only a small amount of mefloquine is renally eliminated; not removed by hemodialysis.</p></div>
<div class="block dohp drugH1Div" id="F51130261"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, half-life may be prolonged and plasma levels may be higher in patients with hepatic impairment; use with caution.</p></div>
<div class="block adr drugH1Div" id="F192194"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Abnormal dreams (14%) (Tickell-Painter 2017), insomnia (13%) (Tickell-Painter 2017)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Gastrointestinal: Vomiting (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, extrasystoles, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, pruritus, telogen effluvium</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, dizziness, emotional disturbance</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, diarrhea, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit, leukopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (transient)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, fatigue, headache</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular block (including first-degree atrioventricular block), cardiac arrhythmia (including atrial flutter) (Fonteyne 1996), cardiac conduction disorder (transient), chest pain, ECG changes (including abnormal T waves on ECG, prolonged QT interval on ECG), edema, flushing, hypertension, hypotension, palpitations, sinoatrial nodal rhythm disorder, sinus bradycardia, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, erythema of skin, hyperhidrosis, Stevens-Johnson syndrome, toxic epidermal necrolysis (McBride 1997), urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia, loose stools</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, leukocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic disease (including hepatic failure)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity angiitis (White 1995), hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, agitation (Tran 2006), anxiety (Tran 2006), ataxia, confusion (Nevin 2017), delusion (Tran 2006), depression, drowsiness, emotional lability, encephalopathy (Nevin 2017), hallucination (Tor 2006), illusion (Borruat 2001), malaise, mania (Tor 2006), memory impairment, myasthenia, panic attack, paranoid ideation (Tran 2006), paresthesia, polyneuropathy (peripheral) (Chester 2011), psychotic reaction (Tran 2006), restlessness, seizure (Nevin 2017), sensorimotor neuropathy, suicidal ideation (Tran 2006), tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, muscle cramps, rhabdomyolysis (Comelli 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (Jain 2016), cataract, diplopia (Jain 2016), optic neuropathy, retinopathy (including central serous chorioretinopathy) (Jain 2016), visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, pneumonitis (Soentjens 2006)</p></div>
<div class="block coi drugH1Div" id="F192209"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to mefloquine, related compounds (eg, quinine and quinidine), or any component of the formulation; prophylactic use in patients with a history of seizures or psychiatric disorder (including active or recent history of depression, generalized anxiety disorder, psychosis, schizophrenia, or other major psychiatric disorders)</p></div>
<div class="block war drugH1Div" id="F192191"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Agranulocytosis/aplastic anemia: Agranulocytosis and aplastic anemia have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Altered cardiac conduction: Mefloquine may cause alterations in the ECG including sinus bradycardia, sinus arrhythmia, first-degree AV block, QT-interval prolongation, and abnormal T waves. Use caution or avoid concomitant use of agents known to cause QT-interval prolongation (eg, halofantrine, quinine, quinidine).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropsychiatric effects: May cause neuropsychiatric adverse effects that can persist after mefloquine has been discontinued. During prophylactic use, if symptoms occur, discontinue therapy and substitute an alternative medication. Symptoms may develop early in the course of therapy. Due to the difficulty in identifying these symptoms in infants and children, monitor closely especially in pediatric patients. Psychiatric symptoms may include anxiety, paranoia, depression, hallucinations, and psychosis. Suicidal ideation and suicide have also been reported. Neurologic symptoms of dizziness or vertigo, tinnitus, and loss of balance may also occur and have been reported to be permanent in some cases. During prophylactic use, the occurrence of psychiatric symptoms such as acute anxiety, depression, restlessness, or confusion may be a prodrome to more serious neuropsychiatric adverse reactions. Use caution in activities requiring alertness and fine motor coordination (eg, driving, piloting planes, operating machinery) with neurologic symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with significant cardiac disease; ECG changes (eg, sinus bradycardia, sinus arrhythmia, first-degree AV block, QT-interval prolongation, abnormal T waves) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; elimination may be prolonged.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropsychiatric disorders: Do not prescribe for prophylaxis in patients with major psychiatric disorders including patients with active depression, a recent history of depression, generalized anxiety disorder, psychosis, schizophrenia; use is contraindicated in these patients. Use with caution in patients with a previous history of depression.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: Eye disorders (including optic neuropathy and retinal disorders) have been reported during treatment. If visual symptoms develop during treatment, prompt ophthalmologic evaluation is warranted; discontinuation of therapy may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• <i>Plasmodium falciparum</i> infections: Appropriate use: In cases of life-threatening, serious, or overwhelming malaria infections due to <i>Plasmodium falciparum</i>, patients should be treated with intravenous antimalarial drug. Mefloquine may be given orally to complete the course.</p>
<p style="text-indent:-2em;margin-left:4em;">• <i>Plasmodium vivax</i> infections: Appropriate use: In cases of acute <i>Plasmodium vivax</i> infection treated with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (eg, primaquine) to avoid relapse.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: When using for treatment, use with caution in patients with a history of seizures; may increase risk of seizures. Prophylactic use is contraindicated in patients with seizure disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Early vomiting leading to treatment failure in children has been reported in some studies; consider alternate therapy if a second dose is not tolerated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not recommended for the treatment of malaria acquired in certain parts of Southeast Asia due to drug resistance (CDC 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• Prolonged use: If mefloquine is to be used for a prolonged period, liver function tests, evaluations for neuropsychiatric effects, and ophthalmic examinations should be performed periodically.</p></div>
<div class="block foc drugH1Div" id="F192203"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p></div>
<div class="block geq drugH1Div" id="F192187"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323363"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Mefloquine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $10.59 - $13.55</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867447"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg</p></div>
<div class="block adm drugH1Div" id="F192206"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer with food and at least 240 mL of water. When used for malaria prophylaxis, dose should be taken once weekly on the same day each week. If vomiting occurs within 30 minutes after the dose, an additional full dose should be given; if it occurs within 30 to 60 minutes after dose, an additional half-dose should be given. If vomiting recurs, monitor closely and consider alternative treatment. Tablets may be crushed and suspended in a small amount of water, milk, or another beverage for persons unable to swallow tablets.</p></div>
<div class="block admp drugH1Div" id="F52613241"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food and with an adequate amount of water (eg, 240 mL of water for adults). For patients unable to swallow tablets or unable to tolerate the bitter taste, crush tablets and mix with a small amount of water, milk, or other food/beverage immediately before administration. Pulverized dose of mefloquine can be enclosed in a gelatin capsule to mask bitter taste (CDC 2023; Schlagenhauf 2011; WHO 2020; manufacturer's labeling). If vomiting occurs within 30 minutes after a dose, repeat dose. If vomiting occurs within 30 to 60 minutes after a dose, an additional half-dose should be administered. If vomiting recurs, monitor closely and consider alternative treatment. When used for malaria prophylaxis, dose should be taken on the same day each week.</p></div>
<div class="block meg drugH1Div" id="F7874703"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2009%2F019591s026s028lbl.pdf%23page%3D13&amp;token=gbeo0SiQdEMzrV46063bm0JRJmUOTJolr3vswrkGih9lum3B%2Fgtdc3izmDID1EtL%2B1rTa9WrJZ4QmEehXrIQm8zv6hTLsh0%2FWoqNRjjKdMI5lAtLAP7kVhQ00UKfsqsr&amp;TOPIC_ID=9602" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf#page=13</a>, must be dispensed with this medication.</p></div>
<div class="block use drugH1Div" id="F192204"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, prophylaxis:</b> Prophylaxis of <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> malaria infections, including prophylaxis of chloroquine-resistant strains of <i>P. falciparum</i>.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, uncomplicated, treatment:</b> Treatment of uncomplicated malaria caused by mefloquine-susceptible strains of <i>P. falciparum</i> (chloroquine-susceptible and -resistant strains) or by <i>P. vivax</i>. <b>Note:</b> The CDC and World Health Organization guidelines also include mefloquine as an option for treatment of uncomplicated malaria due to non-falciparum <i>Plasmodium </i>species (CDC 2020; WHO 2022).</p></div>
<div class="block mst drugH1Div" id="F21645017"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Mefloquine may be confused with Malarone</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lariam [multiple international markets] may be confused with Levaquin [Argentina, Brazil, US, Venezuela]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F192262"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F192196"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoquinolines (Antimalarial): May enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of an aminoquinoline antimalarial.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiseizure Agents: Mefloquine may diminish the therapeutic effect of Antiseizure Agents. Mefloquine may decrease the serum concentration of Antiseizure Agents.  Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If antiseizure drugs are being used for another indication, monitor antiseizure drug concentrations and treatment response closely with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Artemether and Lumefantrine.  Management: Artemether/lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option. If combined, monitor patients for increased toxicities of both agents, including QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: Mefloquine may diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Mefloquine. Mefloquine may decrease the serum concentration of CarBAMazepine.  Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If carbamazepine is being used for another indication, monitor for decreased concentrations and efficacy of both carbamazepine and mefloquine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: Mefloquine may enhance the bradycardic effect of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Antimalarial Agents may increase the serum concentration of ChlorproMAZINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Mefloquine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Mefloquine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Mefloquine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Consider avoidance of this combination when possible. If combined, closely monitor for signs/symptoms of hemolytic reactions. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Mefloquine may diminish the therapeutic effect of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Mefloquine. Mefloquine may decrease the serum concentration of Fosphenytoin-Phenytoin.  Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If fosphenytoin/phenytoin is being used for another indication, monitor for decreased concentrations and efficacy of both phenytoin and mefloquine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: Mefloquine may enhance the QTc-prolonging effect of Halofantrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May increase the serum concentration of Mefloquine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: Mefloquine may diminish the therapeutic effect of PHENobarbital. PHENobarbital may decrease the serum concentration of Mefloquine. Mefloquine may decrease the serum concentration of PHENobarbital.  Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If phenobarbital is being used for another indication, monitor for decreased concentrations and efficacy of both phenobarbital and mefloquine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: Mefloquine may diminish the therapeutic effect of Primidone. Primidone may decrease the serum concentration of Mefloquine. Mefloquine may decrease the serum concentration of Primidone.  Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If primidone is being used for another indication, monitor for decreased concentrations and efficacy of both primidone/phenobarbital and mefloquine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: May enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of quinidine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinidine (Non-Therapeutic): May enhance the adverse/toxic effect of Mefloquine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: May enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of quinine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Mefloquine may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F192224"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Food increases bioavailability by ~40%. Management: Take with food and at least 8 ounces of water. Maintain adequate nutrition and hydration, unless instructed to restrict fluid intake.</p></div>
<div class="block pri drugH1Div" id="F192212"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Mefloquine crosses the placenta; however, clinical experience with mefloquine has not shown an increased risk of adverse effects in pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">Malaria infection in patients who are pregnant may be more severe than in patients who are not pregnant and has a high risk of maternal and perinatal morbidity and mortality. Malaria infection during pregnancy can lead to miscarriage, premature delivery, low birth weight, congenital infection, and/or perinatal death. Therefore, patients who are pregnant and patients who are likely to become pregnant are advised to avoid travel to malaria-risk areas. When travel is unavoidable, patients who are pregnant should take precautions to avoid mosquito bites and use effective prophylactic medications (CDC 2020; CDC Yellow Book 2020).</p>
<p style="text-indent:0em;margin-top:2em;">When other treatment options are not available, mefloquine may be used for the treatment of chloroquine-resistant uncomplicated malaria in pregnancy. In patients who are pregnant with severe malaria, mefloquine may be used as interim oral therapy when the preferred IV agent is not readily available and other oral agents are not available (discontinue once IV treatment is initiated) (consult current CDC guidelines) (CDC 2020).</p></div>
<div class="block brc drugH1Div" id="F192213"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine concentrations in breast milk are ~3% to 4% of a 250 mg dose. The manufacturer recommends that caution be exercised when administering mefloquine to patients who are breastfeeding. Mefloquine is considered acceptable for use in patients who are breastfeeding (CDC Yellow Book 2020).</p></div>
<div class="block dic drugH1Div" id="F192214"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with food and with at least 240 mL of water.</p></div>
<div class="block mop drugH1Div" id="F192200"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">When use is prolonged, periodic liver function tests, evaluations for neuropsychiatric effects, and ocular examinations </p></div>
<div class="block pha drugH1Div" id="F192190"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Mefloquine is a quinoline-methanol compound structurally similar to quinine; mefloquine's effectiveness in the treatment and prophylaxis of malaria is due to the destruction of the asexual blood forms of the malarial pathogens that affect humans, <i>Plasmodium falciparum</i>, <i>P. vivax</i></p></div>
<div class="block phk drugH1Div" id="F192208"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Well absorbed; interpatient variability with rate observed (WHO, 2010); more complete absorption when administered as a suspension compared with tablets</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Distributes into tissues, erythrocytes, blood, urine, CSF </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">V<sub>d</sub>: Children 4 to 10 years: Mean: ~18 to 19 L/kg (Price 1999); Adults: ~20 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~98% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensively hepatic primarily by CYP3A4 to 2,8-bis-trifluoromethyl-4-quinoline carboxylic acid (inactive) and other metabolites</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Increased by food</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Children 4 to 10 years: Mean range: 11.6 to 13.6 days (range: 6.5 to 33 days) (Price 1999); Adults: ~3 weeks (range: 2 to 4 weeks); may be decreased during infection (2 weeks) (WHO 2010)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: ~17 hours (range: 6 to 24 hours)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily bile and feces; urine (9% of total dose as unchanged drug, 4% of total dose as primary metabolite)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038673"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Eloquine | Mephaquine</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Tropicur</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Lfm mefloquina | Lqfex mefloquina</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Mephaquin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Mephaquin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Mephaquin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Mephaquin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Apo-mefloquine | Lariam</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Mephaquin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Mephaquin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Lariam roche</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Mephaquin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Confal | Falcitab | Falcital | Lariam | Larimef | Mefax | Mefcy | Meflar | Mefliam | Mefloc | Mefloquin hcl | Meflotas | Mefque | Mephaquin | Mqf</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Mephaquin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Mefliam | Mephaquin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Eloquine | Mephaquin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Lariam kohlpharma | Mephaquin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Mephaquin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Mephaquin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Mefloquina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Mala | Maqin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Mefloquine HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Mefloquina | Mephaquin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Mephaquin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Eloquine</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Mefloquine</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Eloquine | Mephaquin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Meflotas | Mephaquin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Eloquine | Lariam | Mephaquin | Mequin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apo-mefloquine | Lariam | Mephaquin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Lariam</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Lariam | Mefliam</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Meflotas</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11468119">
<a name="11468119"></a>Borruat FX, Nater B, Robyn L, Genton B. Prolonged visual illusions induced by mefloquine (Lariam): a case report. <i>J Travel Med</i>. 2001;8(3):148-149. doi:10.2310/7060.2001.24461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/11468119/pubmed" id="11468119" target="_blank">11468119</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC). Treatment of malaria: guidelines for clinicians (United States). <a href="https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html" target="_blank">https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html</a>. Updated May 29, 2020. Accessed June 8, 2020.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention. <i>CDC Yellow Book 2020: Health Information for International Travel</i>. Oxford University Press; 2019. <a href="https://wwwnc.cdc.gov/travel/page/yellowbook-home-2014" target="_blank">http://wwwnc.cdc.gov/travel/page/yellowbook-home-2014</a>
</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention. Malaria. In: <i>CDC Yellow Book 2024: Travel-Associated Infections &amp; Diseases.</i> Oxford University Press; 2023. <a href="https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria" target="_blank">https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22144435">
<a name="22144435"></a>Chester AC, Sandroni P. Case report: peripheral polyneuropathy and mefloquine prophylaxis. <i>Am J Trop Med Hyg</i>. 2011;85(6):1008-1009. doi:10.4269/ajtmh.2011.11-0412<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/22144435/pubmed" id="22144435" target="_blank">22144435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27103081">
<a name="27103081"></a>Comelli I, Lippi G, Magnacavallo A, Cervellin G. Mefloquine-associated rhabdomyolysis. <i>Am J Emerg Med</i>. 2016;34(11):2250.e5-2250.e6. doi:10.1016/j.ajem.2016.03.059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/27103081/pubmed" id="27103081" target="_blank">27103081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8957602">
<a name="8957602"></a>Fonteyne W, Bauwens A, Jordaens L. Atrial flutter with 1:1 conduction after administration of the antimalarial drug mefloquine. <i>Clin Cardiol</i>. 1996;19(12):967-968. doi:10.1002/clc.4960191213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/8957602/pubmed" id="8957602" target="_blank">8957602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1431270">
<a name="1431270"></a>Horowitz H and Carbonaro CA, “Inhibition of the <i>Salmonella</i> Typhi Oral Vaccine Strain, Ty21a, by Mefloquine and Chloroquine,” <i>J Infect Dis</i>, 1992, 166(6):1462-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/1431270/pubmed" id="1431270" target="_blank">1431270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27799060">
<a name="27799060"></a>Jain M, Nevin RL, Ahmed I. Mefloquine-associated dizziness, diplopia, and central serous chorioretinopathy: a case report. <i>J Med Case Rep</i>. 2016;10(1):305. doi:10.1186/s13256-016-1091-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/27799060/pubmed" id="27799060" target="_blank">27799060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8996426">
<a name="8996426"></a>McBride SR, Lawrence CM, Pape SA, Reid CA. Fatal toxic epidermal necrolysis associated with mefloquine antimalarial prophylaxis. <i>Lancet</i>. 1997;349(9045):101. doi:10.1016/s0140-6736(05)60884-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/8996426/pubmed" id="8996426" target="_blank">8996426</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Mefloquine [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; January 2021.</div>
</li>
<li>
<div class="reference">
                  Mefloquine [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc; March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28063022">
<a name="28063022"></a>Nevin RL, Leoutsakos JM. Identification of a syndrome class of neuropsychiatric adverse reactions to mefloquine from latent class modeling of FDA adverse event reporting system data. <i>Drugs R D</i>. 2017;17(1):199-210. doi:10.1007/s40268-016-0167-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/28063022/pubmed" id="28063022" target="_blank">28063022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2183998">
<a name="2183998"></a>Panisko DM and Keystone JS, “Treatment of Malaria - 1990,” <i>Drugs</i>, 1990, 39(2):160-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/2183998/pubmed" id="2183998" target="_blank">2183998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9925529">
<a name="9925529"></a>Price R, Simpson JA, Teja-Isavatharm P, et al. Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria. <i>Antimicrob Agents Chemother</i>. 1999;43(2):341-346.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/9925529/pubmed" id="9925529" target="_blank">9925529</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21981927">
<a name="21981927"></a>Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Bansod S, Rhein HG. Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data. <i>Malar J</i>. 2011;10:292. doi:10.1186/1475-2875-10-292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/21981927/pubmed" id="21981927" target="_blank">21981927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16706949">
<a name="16706949"></a>Soentjens P, Delanote M, Van Gompel A. Mefloquine-induced pneumonitis. <i>J Travel Med</i>. 2006;13(3):172-174. doi:10.1111/j.1708-8305.2006.00037.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/16706949/pubmed" id="16706949" target="_blank">16706949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29083100">
<a name="29083100"></a>Tickell-Painter M, Maayan N, Saunders R, Pace C, Sinclair D. Mefloquine for preventing malaria during travel to endemic areas. <i>Cochrane Database Syst Rev</i>. 2017;10:CD006491.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/29083100/pubmed" id="29083100" target="_blank">29083100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16752027">
<a name="16752027"></a>Tor PC, Lee HY, Tan CH. Mefloquine-induced mania in a 22-year-old Chinese man. <i>Singapore Med J</i>. 2006;47(6):549-550.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/16752027/pubmed" id="16752027" target="_blank">16752027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16925829">
<a name="16925829"></a>Tran TM, Browning J, Dell ML. Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report. <i>Malar J</i>. 2006;5:74. doi:10.1186/1475-2875-5-74<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/16925829/pubmed" id="16925829" target="_blank">16925829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7486482">
<a name="7486482"></a>White AC Jr, Gard DA, Sessoms SL. Cutaneous vasculitis associated with mefloquine. <i>Ann Intern Med</i>. 1995;123(11):894. doi:10.7326/0003-4819-123-11-199512010-00024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/7486482/pubmed" id="7486482" target="_blank">7486482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8703186">
<a name="8703186"></a>White NJ, “The Treatment of Malaria,” <i>N Engl J Med</i>, 1996, 335(11):800-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/8703186/pubmed" id="8703186" target="_blank">8703186</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Guidelines for the treatment of malaria. 2010, World Health Organization, Geneva. http://www.who.int/malaria/publications/atoz/9789241549127/en/.</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Guidelines for the treatment of malaria. 2022, World Health Organization, Geneva. https://www.who.int/teams/global-malaria-programme/guidelines-for-malaria. Published June 3, 2022.</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Malaria. In: <i>International Travel and Health</i>. World Health Organization; 2020:chap. 7.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8505942">
<a name="8505942"></a>Wyler DJ, “Malaria Chemoprophylaxis for the Traveler,” <i>N Engl J Med</i>, 1993, 329(1):31-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mefloquine-drug-information/abstract-text/8505942/pubmed" id="8505942" target="_blank">8505942</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9602 Version 304.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
